Insulin Accessibility Crisis
The dominance of three major companies in insulin production has led to soaring prices and limited access, particularly affecting diabetes patients in low and middle-income countries. Despite competition, prices remain high as these companies control 96% of the market. The World Health Organization is now taking steps to improve access by testing and approving quality assured insulin and biosimilars, aiming to broaden availability for those in need.In this clip
From this podcast
Short Wave
There's A Plan To Drive Down Global Insulin Prices. Will It Work?
Related Questions